Hematology Biobank: In Vitro Study of Blood Disorders

This is a biorepository of blood specimens from subjects with different Hematological disorders.

Study Overview

• Status: Recruiting
• Conditions: Hematological Disorders

Detailed Description

There has been a marked increase in our knowledge of Blood Disorders in the last decade. Much of this knowledge comes from examining blood specimens from patients and subjecting these samples to red cell, plasma, serum or DNA analyses. The study team proposes to set up a Hematology biobank, which will include patient histories, their medical progress and a linked but de-identified bank of blood samples. This will enable researchers to have a large database, which can be used to learn more about these diseases.

The Hematology biobank will use whole blood, red blood cells, plasma, serum and/or DNA. Whole blood specimens, which by definition include the white cells that contain DNA, will be collected and stored in the biobank repository at the Institute for Clinical and Translational Research (ICTR) for future studies.

Blood samples will be obtained from two sources:

1. Leftover/discarded whole blood samples that were obtained for standard of care.
2. Blood samples consisting of 1-5 tubes (3-20 ml of whole blood) from patients with written consent. When possible, these samples will be obtained during routine blood draws performed for a typical visit. It may be necessary to ask patients to specifically donate blood for the study.

• Study Type: Observational
• Enrollment (Estimated): 2000

Contacts and Locations

• Study Contact: Name: Swati Goel; Phone Number: 7189204137; Email: swgoel@montefiore.org

Study Locations

• United States
  • New York
    • The Bronx, New York, United States, 10467
      • Recruiting
      • Montefiore Medical Center
      • Contact: Swati Goel; Phone Number: 718-920-4137

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

- Adult and pediatric patients 12 years of age and older

Description

Inclusion Criteria:

• Above 12 years of age and referred to the Hematology Division at Montefiore-Einstein
• Under the care of a Montefiore-Einstein hematologist for a hematologic disorder

Exclusion Criteria:

- Do not meet the Inclusion Criteria listed above

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Biobank	To have specimens available for IRB approved studies	5 years

Collaborators and Investigators

• Sponsor: Albert Einstein College of Medicine
• Collaborators: New York Blood Center
• Investigators: Principal Investigator: Henny Billett, Albert Einstein College of Medicine

Study record dates

Study Major Dates

• Study Start: January 1, 2014
• Primary Completion (Estimated): January 1, 2030
• Study Completion (Estimated): January 1, 2030

Study Registration Dates

• First Submitted: May 7, 2015
• First Submitted That Met QC Criteria: May 8, 2015
• First Posted (Estimated): May 13, 2015

Study Record Updates

• Last Update Posted (Estimated): January 6, 2026
• Last Update Submitted That Met QC Criteria: January 2, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: Hematology Biobank
• Additional Relevant MeSH Terms: Hemic and Lymphatic Diseases; Hematologic Diseases
• Other Study ID Numbers: 2013-2918

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: We will enter our deidentified data into REDCap which will make it available to others.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No